fashion -WSS

fashion

author：Wikipedia 2025-09-03 09:27:16 - browse：95

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： White House launches permanent pandemic office

hotspot

WSS

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Stanford president's case begs question: Who takes blame?

Why an extreme heat and wildfire smoke combination can be so dangerous

7 of the most gruesome medical devices in history

FDA official pushes for dedicated emerging pathogens team

Stanford president faces new allegations over 1999 paper

hotspot

fashion

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Stanford president's case begs question: Who takes blame?

How one medical school became remarkably diverse

AbbVie dramatically boosts its spending on lobbying

Hollywood unions extend contract negotiations for actors

Winning ticket for $1 billion Powerball jackpot sold in California

Malaria cases in Florida and Texas: Here’s what you need to know

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Psychedelics group wrestles with new pharma identity

Tesla recalling nearly 16,000 of its 2021

leisure time

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Elizabeth Warren probes abortion access

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Providers still hesitate to prescribe buprenorphine, study finds

What to know about Saharan dust affecting the US and how it can affect health

Tocagen's brain cancer gene therapy trial continues. Investors worry

hotspot

hotspot

hotspot

knowledge